Harrow, INC Form 4 insider transactions

Adrienne L. Graves, a Director at Harrow Inc. (HROW), reported the acquisition of 1,000 shares of common stock on May 18, 2026.

Lauren P. Silvernail, a Director at Harrow, Inc., acquired 1,000 shares of common stock on May 18, 2026.

Amir Shojaei, Chief Scientific Officer of Harrow Inc., received a grant of 10,000 restricted stock units.

Harrow Inc. CEO Mark L. Baum acquired 10,000 shares of common stock in a series of transactions.

Andrew R. Boll, President and CFO of Harrow, Inc., acquired 3,500 shares of common stock through open market purchases.

Opaleye Management Inc., a 10% owner of Harrow, Inc., reported selling 198,572 shares of common stock over two days in early March 2026.

Opaleye Management, a 10% owner and director of Harrow, Inc., filed a Form 4 disclosing a pre-planned sale of 5,000 common shares scheduled for February 27, 2026, at $54.18 per share.

Harrow, Inc.'s Chief Commercial Officer, Patrick Sullivan, was granted 40,000 Restricted Stock Units with both performance and time-based vesting conditions.

Opaleye Management Inc., a 10% owner of HARROW, INC., reported the sale of 20,000 shares of common stock at a weighted average price of $53.3457.

Harrow, Inc.'s President and CFO, Andrew R. Boll, exercised stock options and had shares withheld for tax purposes, increasing his direct beneficial ownership of common stock.

Harrow, Inc. CEO Mark L. Baum exercised stock options for 180,000 shares and increased his direct beneficial ownership to 2,986,130 shares.

Harrow, Inc. has granted its Chief Accounting Officer, Randall E. Pollard, 30,000 stock options with an exercise price of $39, vesting over four years.

Harrow, Inc. CEO Mark L. Baum exercised 600,000 stock options and increased his direct beneficial ownership of common stock to 2,886,124 shares after accounting for shares withheld for taxes and cashless exercise.

Harrow, Inc.'s Chief Financial Officer, Andrew R. Boll, has been granted 405,750 performance-based restricted stock units (PSUs) under the company's 2025 Stock Incentive and Awards Plan, contingent on a three-year service period and aggressive stock price achievements.

Harrow, Inc. CEO Mark L. Baum has been granted 889,500 performance-based restricted stock units (PSUs) under the company's 2025 Stock Incentive and Awards Plan, contingent on a three-year service period and achieving stock price targets up to $100 per share.

Harrow Inc. Director Perry J. Sternberg has reported the acquisition of 7,339 Restricted Stock Units as a compensatory award, vesting one year from the grant date of June 20, 2025.

Harrow Inc. Director Lauren P. Silvernail was granted 7,339 Restricted Stock Units as a compensatory award, vesting one year from the grant date of June 20, 2025.

Harrow Inc. Director Adrienne L. Graves reported the acquisition of 7,339 Restricted Stock Units as a compensatory award, vesting in full on June 20, 2026.

Opaleye Management Inc., a significant shareholder and director of Harrow, Inc., reported the sale of 30,204 shares of common stock across two transactions in early June 2025.

Opaleye Management Inc., a significant 10% owner of HARROW, INC. (HROW), reported the sale of 4,796 shares of common stock across two transactions in early June 2025.

Opaleye Management Inc. reports selling shares of Harrow, Inc. common stock in multiple transactions, reducing its beneficial ownership.

Opaleye Management Inc. files an amended Form 4 to correct an error in a previous filing regarding transactions in Harrow, Inc. (HROW) stock.

Opaleye Management Inc. filed an amended Form 4 to correct an error in a previous filing regarding a transaction in Harrow, Inc. (HROW) stock.

Andrew Boll, CFO of Harrow Inc., reports the vesting of performance stock units (PSUs) and subsequent transactions, including shares withheld for tax purposes.

John P. Saharek, CEO & President of ImprimisRx at Harrow Inc., reports acquisition and disposal of common stock related to performance stock units (PSUs) vesting.

Harrow Inc.'s CEO, Mark Baum, acquired and disposed of shares following the vesting of performance stock units (PSUs) granted in 2023.

Opaleye Management Inc. reports a disposition of 5,000 shares of Harrow Inc. common stock at a price of $30.011 per share.

Opaleye Management Inc. reports a disposition of 5,000 shares of Harrow, Inc. common stock at a price of $29.64 per share.

Opaleye Management Inc. reports the sale of 5,000 shares of Harrow, Inc. common stock at $28.05 per share on February 28, 2025.

Opaleye Management Inc., a 10% owner of Harrow Inc., sold 20,000 shares of common stock at an average price of $35.5907 per share on January 22, 2025.